Artificial intelligence and allergic rhinitis: does ChatGPT increase or impair the knowledge?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background Optimal management of allergic rhinitis requires patient education with easy access to accurate information. However, previous online platforms have provided misleading information. The demand for online medical information continues to grow, especially with the introduction of advanced chatbots like ChatGPT. Methods This study aimed to evaluate the quality of information provided by ChatGPT regarding allergic rhinitis. A Likert scale was used to assess the accuracy of responses, ranging from 1 to 5. Four authors independently rated the responses from a healthcare professional’s perspective. Results A total of 20 questions covering various aspects of allergic rhinitis were asked. Among the answers, eight received a score of 5 (no inaccuracies), five received a score of 4 (minor non-harmful inaccuracies), six received a score of 3 (potentially misinterpretable inaccuracies) and one answer had a score of 2 (minor potentially harmful inaccuracies). Conclusions The variability in accuracy scores highlights the need for caution when relying solely on chatbots like ChatGPT for medical advice. Patients should consult qualified healthcare professionals and use online sources as a supplement. While ChatGPT has advantages in medical information delivery, its use should be approached with caution. ChatGPT can be useful for patient education but cannot replace healthcare professionals.

TidsskriftJournal of Public Health (United Kingdom)
Udgave nummer1
Sider (fra-til)123-126
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
HM reports receiving honoraria for lectures or advisory board meetings from GSK, Teva, Novartis, Sanofi-Aventis, Airsonett AB, and ALK-Abelló Nordic A/S not related to this study within the past 5 years. Dr HM has received research grant from ALK-Abelló A/S outside this study. Outside the study SFT has been a speaker and/or advisor for Sanofi, AbbVie, LEO Pharma, Pfizer, Eli Lilly, Novartis, UCB Pharma, Almirall, Union Therapeutics and Janssen Pharmaceuticals; and has received research support from Sanofi, AbbVie, LEO Pharma, Novartis, UCB Pharma and Janssen Pharmaceuticals. The remaining authors have no conflicts of interest to report.

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of Faculty of Public Health.

ID: 385520361